Former J&J Executive Herwig Janssen Appointed Chairman of Tryptamine Therapeutics as Company Advances Psilocin-Based Clinical Programs
Key Insights
Tryptamine Therapeutics (search) has appointed Herwig Janssen, a former Johnson & Johnson executive with 40+ years of pharmaceutical experience, as its new non-executive chairman effective May 12.
The leadership change comes as Tryptamine prepares for pivotal clinical trials of TRP-8803, an IV-infused psilocin formulation being developed to treat binge eating disorder (search), fibromyalgia (search), and irritable bowel syndrome (search).
Chris Ntoumenopoulos will transition from non-executive to executive director, strengthening the company's leadership team ahead of key clinical and commercial milestones in psychedelic-assisted therapeutics.
Tryptamine Therapeutics (search) Ltd has appointed former Johnson & Johnson executive Herwig Janssen as its new non-executive chairman, signaling a strategic board refresh as the company prepares to advance its lead psychedelic drug candidate into pivotal clinical trials.
Janssen, who brings more than 40 years of pharmaceutical industry experience including 27 years as a vice president in J&J's pharmaceutical division, will assume the role effective May 12. The appointment comes at a critical juncture as Tryptamine positions itself to launch advanced clinical trials for TRP-8803, an intravenously infused psilocin formulation targeting binge eating disorder (search) (BED).
"As we advance to the next phase of trials, I look forward to leveraging my experience in international healthcare markets to help guide the strategic direction of the business," said Janssen, who is already a shareholder in the company. He noted that he was attracted by Tryptamine's pioneering work and the therapeutic potential of psychedelic-assisted treatments.
Strategic Leadership Transition
The leadership changes extend beyond Janssen's appointment. Chris Ntoumenopoulos, who joined as a non-executive director in May 2024, will transition to the role of executive director. Ntoumenopoulos brings substantial biotech experience, having held senior positions at Race Oncology and ResApp Health (which was acquired by Pfizer), and currently serves as chairman of NeuroScientific Biopharmaceuticals (search).
These appointments coincide with the departure of outgoing chairman Mark Davies, who will step down on May 12. During his tenure, Davies oversaw several significant milestones, including the acquisition of Tryp Therapeutics (search), a successful $6 million capital raise, and the completion of Phase 1 clinical trials.
Tryptamine CEO Jason Carroll emphasized the strategic importance of these board changes: "With decades of experience as a senior global healthcare executive, we look forward to benefiting from Herwig's insights at board level. Chris's move into a more hands-on executive role reflects our commitment to building an experienced, agile leadership team as we prepare to launch our next phase of clinical trials."
Extensive Pharmaceutical Experience
Janssen's credentials are particularly relevant to Tryptamine's growth ambitions. During his nearly three decades at Johnson & Johnson, he led business development and deal execution across emerging markets, facilitating licensing deals, acquisitions, co-promotions, and technology transfers. His work in building innovative healthcare ecosystems earned him J&J's highest internal recognition, the James E. Burke award for leadership and impact.
Advancing Psychedelic Medicine Programs
Tryptamine is currently progressing multiple clinical programs using psilocin-based therapies. Beyond binge eating disorder (search), the company is exploring applications for fibromyalgia (search) and irritable bowel syndrome (search)—conditions with significant unmet medical needs affecting millions globally.
The company's lead candidate, TRP-8803, represents an innovative approach to psychedelic medicine. By delivering psilocin—the active metabolite of psilocybin—directly via intravenous infusion, the treatment aims to provide more controlled and predictable therapeutic effects compared to oral administration of traditional psychedelics.
Positioning in the Emerging Psychedelics Market
The board restructuring positions Tryptamine to capitalize on growing scientific and regulatory interest in psychedelic-assisted therapies. As clinical evidence accumulates for the potential of compounds like psilocin in treating mental health and neurological conditions, companies with advanced clinical programs and experienced leadership are likely to gain competitive advantages.
With Janssen's extensive experience in international healthcare markets and pharmaceutical commercialization, Tryptamine appears to be strengthening its capabilities not just for clinical development but also for potential future commercialization pathways.
The leadership changes reflect a broader trend in the psychedelic medicine sector, where companies are increasingly recruiting executives with traditional pharmaceutical backgrounds to navigate the complex regulatory and commercial landscape as these novel therapies approach potential market approval.